Targovax announces financing of up to NOK 300m over three years to advance its clinical cancer programs & pre-clinical circular RNA platform
· The financing will support initiation of the ONCOS-102 melanoma phase 2 and TG01 mutant RAS clinical trials and in vivo PoC studies for the ground-breaking circRNA program · The convertible bond facility with London-based Atlas Capital Markets provides a secured and flexible source of capital to advance all of Targovax´s three R&D pillars · Additional actions are being pursued in parallel to unlock the full potential of Targovax’s emerging circRNA platform Oslo, Norway, 16 February 2023 - Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune